More specifically, the humanized anti-C5 antibody (eculizumab) is widely used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (22). This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.